Today: 20 January 2026
Subscribe
Browse Category

Drug Pricing News 17 November 2025 - 21 December 2025

AbbVie Stock Week Ahead (Dec. 22–26, 2025): ABBV Holds Near $227 as Drug-Pricing Headlines Collide With Fresh Analyst Upgrades

AbbVie Stock Week Ahead (Dec. 22–26, 2025): ABBV Holds Near $227 as Drug-Pricing Headlines Collide With Fresh Analyst Upgrades

As of Sunday, December 21, 2025, AbbVie Inc. (NYSE: ABBV) heads into a holiday-shortened trading week with shares hovering near the mid-$220s, after a high-volume rebound into Friday’s close. The setup for the week ahead is defined by two competing forces: strong underlying fundamentals (Skyrizi/Rinvoq momentum, updated 2025 outlook, and a higher dividend) and a renewed policy overhang as Washington…
21 December 2025
····
Healthcare Stocks Outlook (Dec. 21, 2025): Drug-Price Deals, ACA Premium Shock, and 2026 Catalysts Investors Are Watching

Healthcare Stocks Outlook (Dec. 21, 2025): Drug-Price Deals, ACA Premium Shock, and 2026 Catalysts Investors Are Watching

Sunday, December 21, 2025 — With U.S. markets heading into a holiday-shortened final trading stretch, healthcare stocks are back in focus as investors weigh a year-end “Santa rally” against a fast-moving policy backdrop that is unusually direct for the sector: drugmakers cutting prices through White House deals, insurers staring down a subsidy cliff tied to the Affordable Care Act (ACA),…
21 December 2025
···
Pharma Stocks Week Ahead (Dec. 22–26, 2025): Drug-Pricing Deals, FDA Catalysts, and M&A to Watch

Pharma Stocks Week Ahead (Dec. 22–26, 2025): Drug-Pricing Deals, FDA Catalysts, and M&A to Watch

Christmas week is usually about thin liquidity and shorter trading hours, not blockbuster headlines. But pharma and biotech stocks head into the final full week of the year with a rare mix of policy shockwaves, deal-making, and FDA-driven volatility—all clustered around Dec. 19–21, 2025. From the White House’s sweeping “most-favored-nation” (MFN) push on U.S. drug prices to BioMarin’s largest-ever acquisition…
21 December 2025
···
Pfizer Stock (PFE) in Focus: 2026 Guidance, Drug-Price Deal Pressures, and Pipeline Catalysts Investors Are Watching

Pfizer Stock (PFE) in Focus: 2026 Guidance, Drug-Price Deal Pressures, and Pipeline Catalysts Investors Are Watching

Dec. 21, 2025 — Pfizer Inc. (NYSE: PFE) ends the week in the spotlight after management laid out a 2026 outlook that undershot some Wall Street expectations, while a string of pipeline updates, partnerships, and policy headlines reshaped the near-term narrative around the long-time pharma bellwether. Reuters Pfizer stock last closed at $25.25 on Friday, Dec. 19, with investors weighing…
21 December 2025
····
Gilead Sciences Stock (NASDAQ: GILD) Today: TrumpRx Drug-Pricing Deal, HIV Pipeline Momentum, and Wall Street Forecasts (Dec. 20, 2025)

Gilead Sciences Stock (NASDAQ: GILD) Today: TrumpRx Drug-Pricing Deal, HIV Pipeline Momentum, and Wall Street Forecasts (Dec. 20, 2025)

Updated: December 20, 2025 Gilead Sciences, Inc. (NASDAQ: GILD) heads into the weekend with fresh policy headlines, a high-profile pricing agreement tied to the Trump administration’s TrumpRx initiative, and renewed attention on the company’s next-generation HIV portfolio. The combination has kept Gilead stock near the top of its recent trading range—while also reopening the debate investors have wrestled with all…
20 December 2025
···
AbbVie Stock (ABBV) News Today: Drug-Pricing Deal Watch, Skyrizi/Rinvoq Momentum, and Fresh Wall Street Forecasts (Dec. 20, 2025)

AbbVie Stock (ABBV) News Today: Drug-Pricing Deal Watch, Skyrizi/Rinvoq Momentum, and Fresh Wall Street Forecasts (Dec. 20, 2025)

December 20, 2025 — AbbVie Inc. (NYSE: ABBV) is closing out the week in the spotlight as U.S. drug-pricing policy headlines collide with a still-strong “post-Humira” growth narrative built around Skyrizi and Rinvoq. The stock finished the last regular session (Friday, Dec. 19) at $226.82, up 1.80%, while trading volume surged well above its recent average — a sign that…
20 December 2025
····
Healthcare Stocks News Today: Drug Pricing Shake-Up, Biotech M&A, IPO Momentum, and 2026 Outlook (Dec. 20, 2025)

Healthcare Stocks News Today: Drug Pricing Shake-Up, Biotech M&A, IPO Momentum, and 2026 Outlook (Dec. 20, 2025)

As of December 20, 2025, healthcare stocks are heading into year-end with a rare mix of policy clarity and policy risk—often at the same time. In the past 48 hours, the sector has been hit by major U.S. drug-pricing announcements, renewed focus on insurance premiums, and a fresh run of deal and IPO headlines that are reshaping investor expectations for…
20 December 2025
····
Pfizer Stock (PFE) News Today: 2026 Guidance, TrumpRx Drug-Pricing Deals, Dividend, and Analyst Forecasts (Dec. 20, 2025)

Pfizer Stock (PFE) News Today: 2026 Guidance, TrumpRx Drug-Pricing Deals, Dividend, and Analyst Forecasts (Dec. 20, 2025)

Pfizer Inc. stock (NYSE: PFE) is ending the week in a familiar place: the mid-$20s. But the story behind that “quiet” price is anything but quiet. Investors are weighing Pfizer’s newly issued 2026 outlook, an evolving U.S. drug-pricing landscape tied to the TrumpRx / most-favored-nation (MFN) framework, and a pipeline-and-deal strategy meant to carry the company through a multi-year patent…
20 December 2025
····
Merck (MRK) Stock After Hours on Dec. 19, 2025: Trump Drug-Pricing Deal, FDA Fast-Track Vouchers, and What to Watch Before Markets Reopen

Merck (MRK) Stock After Hours on Dec. 19, 2025: Trump Drug-Pricing Deal, FDA Fast-Track Vouchers, and What to Watch Before Markets Reopen

Merck & Co., Inc. (NYSE: MRK) finished Friday’s regular session (Dec. 19, 2025) modestly higher, then eased slightly in after-hours trading as investors digested a headline-heavy day featuring U.S. drug-pricing policy moves and FDA acceleration for two major Merck pipeline assets. Below is what happened after the bell, why it matters, and the key items to track before the next…
20 December 2025
····
Johnson & Johnson Stock News Today (Dec. 19, 2025): Trump Drug-Price Deals, FDA Wins and Fresh $240 Targets Put JNJ in Focus

Johnson & Johnson Stock News Today (Dec. 19, 2025): Trump Drug-Price Deals, FDA Wins and Fresh $240 Targets Put JNJ in Focus

Johnson & Johnson (NYSE: JNJ) is back on investors’ radar on Friday, December 19, 2025, as Wall Street digests a fast-moving mix of Washington drug-pricing headlines, a string of U.S. FDA decisions across pharma and medtech, ongoing talc litigation, and a wave of updated analyst price targets. JNJ shares traded around $208 intraday, hovering near the flatline as the market…
19 December 2025
····
Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Novo Nordisk Slashes Wegovy and Ozempic Cash Prices to $349, Launches $199 Intro Deals as GLP‑1 Price War Escalates

Published November 17, 2025 Novo Nordisk moved aggressively today to cut out‑of‑pocket costs for its blockbuster GLP‑1 drugs Wegovy and Ozempic, unveiling new self‑pay prices and limited‑time offers that it says will reach tens of thousands of U.S. pharmacies and telehealth partners. The changes come just days after the Trump administration struck landmark pricing agreements with Novo Nordisk and Eli…
17 November 2025
··
LifeMD (LFMD) Slashes Wegovy and Ozempic Cash-Pay Price to $199 as Q3 2025 Earnings and GLP‑1 Price War Heat Up

LifeMD (LFMD) Slashes Wegovy and Ozempic Cash-Pay Price to $199 as Q3 2025 Earnings and GLP‑1 Price War Heat Up

LifeMD (NASDAQ: LFMD) announced the lowest nationwide cash-pay pricing for Wegovy and Ozempic at $199 per month for new patients, just hours before its rescheduled Q3 2025 earnings release. Here’s what it means for patients, investors, and the GLP‑1 weight-loss market LifeMD Announces $199 Cash-Pay Pricing for Wegovy and Ozempic This morning, LifeMD, Inc. (NASDAQ: LFMD) unveiled what it calls…
17 November 2025
····
1 2 3 4

Stock Market Today

  • Chipotle Stock Forecast 2026-2030: Challenges, Growth, and Market Outlook
    January 20, 2026, 10:06 AM EST. Chipotle Mexican Grill (NYSE: CMG) lowered its full-year same-store sales forecast, citing shifts in consumer spending, which led to a nearly 20% stock decline to a 52-week low of $29.75. Shares are down 25.9% over six months, lagging the S&P 500, though Wall Street analysts maintain a bullish stance with an average buy recommendation and an 11% upside target for the next year. The company faces pressures from inflation, high food costs, and rising labor expenses squeezing margins. Comparable sales slowed in 2025 after years of strong growth. Despite leadership changes, Chipotle plans aggressive expansion, opening more than 4,000 locations with digital-enhanced Chipotlanes and global market entries in Mexico, South Korea, and Singapore set for 2026. Investors should weigh robust growth plans against near-term economic headwinds.
Go toTop